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The recent increase in zoonotic avian influenza A(H7N9) 
disease in China is a cause of public health concern. Most 
of the A(H7N9) viruses previously reported have been of 
low pathogenicity. We report the fatal case of a patient in 
China who was infected with an A(H7N9) virus having a 
polybasic amino acid sequence at its hemagglutinin cleav-
age site (PEVPKRKRTAR/GL), a sequence suggestive 
of high pathogenicity in birds. Its neuraminidase also had 
R292K, an amino acid change known to be associated with 
neuraminidase inhibitor resistance. Both of these molecu-
lar features might have contributed to the patient’s adverse 
clinical outcome. The patient had a history of exposure to 
sick and dying poultry, and his close contacts had no evi-
dence of A(H7N9) disease, suggesting human-to-human 
transmission did not occur. Enhanced surveillance is need-
ed to determine whether this highly pathogenic avian influ-
enza A(H7N9) virus will continue to spread.
Avian influenza A(H7N9) viruses with zoonotic po-tential emerged in East China in early 2013. From 
February 2013 through February 20, 2017, a total of 1,222 
patients with A(H7N9) disease had been reported to the 
World Health Organization, with 304 of these patients 
being reported January 19–February 14, 2017 (1,2). The 
overall case fatality ratio was ≈37%. Most patients with 
A(H7N9) disease primarily had viral pneumonia, with 
some progressing to acute respiratory distress syndrome 
(ARDS). Unlike patients with influenza A(H5N1) disease, 
patients with A(H7N9) disease were more likely to be older 
and have underlying comorbidities (3). In healthy young 
persons with A(H7N9) infections, symptoms were often 
mild, and potentially a substantial proportion of these in-
fections was asymptomatic and not recognized (4–6).
The A(H7N9) virus is a low pathogenicity avian influ-
enza (LPAI) virus that typically causes no signs of disease in 
birds and has become enzootic in poultry. A(H7N9) infections 
have been reported in poultry and humans from 22 provinces 
and municipalities in mainland China, with cases acquired in 
mainland China sometimes being reported in Hong Kong, 
China; Macao, China; Taiwan; Malaysia; and Canada (2).
Phylogenetic analyses of the A(H7N9) hemagglutinin 
(HA) genes showed that the viruses that emerged in the Yang-
tze River Delta region in 2013 rapidly spread to other parts 
of South and South East China and that distinct virus clades 
became established in these different geographic regions (7). 
Genetic analysis of A(H7N9) viruses has revealed some ad-
aptations in the virus HA that allow binding to the sialic acid 
receptors on the epithelium of the mammalian upper respira-
tory tract. Upon infection in humans, these viruses rapidly 
acquire mutations in the viral polymerase basic 2 (PB2) gene 
(8). Unlike A(H5N1) viruses, A(H7N9) viruses efficiently in-
fect and replicate in ex vivo cultures of the human bronchus 
(9) and are transmitted between ferrets, albeit inefficiently, by 
the airborne route (10), indicating the substantial potential for 
efficient human-to-human transmission. Although there have 
been occasional clusters of cases, some likely caused by lim-
ited human-to-human transmission, no evidence of sustained 
human-to-human transmission has been reported (2).
When transmitting among domestic, terrestrial poul-
try, LPAI type A viruses of the H5 and H7 subtypes can 
undergo mutations that lead to multiple basic amino acids 
being present at the HA cleavage site, a signature asso-
ciated with increased pathogenicity in chickens. Such vi-
ruses can disseminate beyond the respiratory and intestinal 
tracts to affect the brain, liver, spleen, and pancreas and are 
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lethal in chicken; these viruses are then designated highly 
pathogenic avian influenza (HPAI) (11,12). Since their 
emergence in 2013, the A(H7N9) viruses have remained 
LPAI viruses in poultry, which has made detection and 
containment of these viruses more challenging than these 
activities were for A(H5N1), an HPAI virus that usually 
caused severe disease in poultry flocks. 
We report the investigation of illness in a patient 
in China infected with an A(H7N9) virus with a novel 
polybasic amino acid sequence at its HA cleavage site, 
a change that corresponds with increased pathogenicity 
in poultry and potentially (although not invariably) in-
creased pathogenicity in humans. Relevant epidemiologic 
information, such as history of contact with poultry and 
evidence of transmission of infection to close contacts, 
is provided.
Methods
The Patient
The patient was a 56-year-old man with diabetes and hy-
pertension who lived in Lianzhou, China, in Guangdong 
Province. He raised chickens in his backyard and noticed 
some of them were sick and dying weeks before his illness. 
Some of these chickens were slaughtered, cooked, and con-
sumed by the patient and his family members.
On January 7, 2017, day 1 of illness, he had a fever 
(39.8°C) and cough; shortly thereafter, shortness of breath 
developed, and on January 10, day 4 of illness, he was ad-
mitted to a local hospital (Figure 1). Bilateral pneumonia 
was diagnosed based on his clinical signs and computed 
tomography (CT) results. The patient’s throat swab from a 
point-of-care test was negative for influenza A/B. Because 
he had a history of contact with poultry, oseltamivir treat-
ment (75 mg 2×/d) was commenced. On day 6, his clinical 
condition deteriorated markedly, with progression to severe 
respiratory failure, hypoxia (oxygen saturation 78.6%), and 
coma. He was transferred to the intensive care unit for in-
vasive mechanical ventilation.
RNA extracted from an endotracheal aspirate acquired 
on day 6 was positive for influenza A(H7N9) virus. On day 
7, he had mild gastrointestinal bleeding and a cardiac ar-
rest. No endoscopy was performed, and he was rescued by 
cardiopulmonary resuscitation and intravenous injection of 
norepinephrine. The size and shape of his heart were within 
reference range. Chest radiography showed he had exten-
sive bilateral infiltration of the lungs with prominent hilar 
shadowing (Figure 2, panel A). The patient had progressed 
Figure 1. Clinical course of 56-year-old man with diabetes and hypertension infected with highly pathogenic avian influenza A(H7N9) 
virus, China, 2017. CT, computed tomography; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; MDR, multidrug 
resistant; NAI, neuraminidase inhibitor; POCT, point-of-care test.
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to severe ARDS. Antiviral therapy was changed from os-
eltamivir to peramivir (0.6 g intravenous 4×/d), and he was 
given antibiotics (cefoperazone sodium/sulbactam sodium 
[2:1], 3 g/8 h). Extracorporeal membrane oxygenation 
(ECMO) was commenced. 
Laboratory tests showed high total leukocyte and neu-
trophil counts and high levels of procalcitonin, aspartate 
aminotransferase, serum creatinine, lactate dehydrogenase, 
blood urea nitrogen, and d-dimers throughout the hospi-
talization (online Technical Appendix Table 1, https://
wwwnc.cdc.gov/EID/article/23/8/17-0600-Techapp1.pdf). 
His hemoglobin level remained low. Continuous renal re-
placement therapy was applied because of increasing renal 
dysfunction (days 8–14). His oxygenation index was main-
tained at around 200 mm Hg by the use of ECMO (Figure 
3). On day 10, treatment with peramivir was stopped and 
oseltamivir recommenced. Viral load in the endotracheal 
aspirate started to decline on day 16 and was undetectable 
on day 20 (Figure 3). However, his clinical condition con-
tinued to deteriorate gradually after removal from ECMO. 
Secondary bacterial infections developed with multidrug- 
resistant Pseudomonas aeruginosa (detected in sputum 
days 9 and 19) and Acinetobacter baumannii (detected in 
blood cultures day 25). Combination antibiotic therapy was 
used to treat these infections (online Technical Appendix 
Table 2). 
Cytomegalovirus (CMV) DNA was detected in pa-
tient serum on day 11 of illness, suggesting CMV re-
activation. Because of the lack of clinical response to 
oseltamivir and antibiotics and the detection of CMV 
DNA in serum, ganciclovir therapy was initiated on day 
32 to suppress possible systemic CMV disease. A CT 
scan of the lungs on day 30 showed multiple bilateral 
patchy hyperdense lesions and bilateral pleural effusions 
(Figure 2, panel B). Repeated electrocardiography trac-
ings did not reveal evidence of myocarditis, and Doppler 
echocardiography examinations showed effective myo-
cardial contraction. CT scan of the brain on the same day 
showed patchy hypodense lesions with unclear borders 
in the left corona radiate and right centrum semiovale 
(Figure 2, panel C), the largest measuring 8 × 10 mm 
with a CT value (8 H) indicative of lacunar infarction. 
The CT scan also showed symmetric, bilateral cerebral 
hemispheres; preservation of gray-white differentiation; 
no obvious lesions in the brain parenchyma; no deepen-
ing or widening of sulci, fissures, and cisterns; no dilata-
tion or deformity in the ventricular system; and no mid-
line shift. However, intracerebral edema was evident 
(Figure 2, panel C). 
On day 40, extensive bilateral shadowing of the lung 
fields with blurring of the costophrenic angles continued to 
be observed on chest radiography (Figure 2, panel D). On 
day 43, the patient died.
Clinical and Epidemiologic Data Collection
The clinical history and epidemiologic information were 
obtained from the patient at hospital admission and from 
relatives during interviews. Progression of clinical symp-
toms and laboratory and radiologic findings were obtained 
by retrospective chart review.
Figure 2. Chest and brain imaging of 56-year-old man infected with highly pathogenic avian influenza A(H7N9) virus, China,  
2017: radiograph imaging of chest at day 7 (A) and day 40 (D); computed tomographic scans of the chest (B) and the brain (C)  
at day 30.
Figure 3. Kinetics of viral load, oxygenation index, and HI 
antibody titers in 56-year-old man infected with highly pathogenic 
avian influenza A(H7N9) virus, China, 2017. Arrows indicate 
the days HI titers and viral titers in serum were acquired. HI, 
hemagglutination inhibition; neg, negative.
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Viral Diagnosis
Serially acquired throat swabs, endotracheal aspirates, se-
rum samples, and fecal samples were collected from the 
patient and stored in viral transport medium. We extract-
ed viral RNA by using QIAamp MinElute Virus Spin kit 
(QIAGEN, Hilden, Germany) according to the manufac-
turer’s instructions. The extracted RNA was subjected to 
reverse transcription and amplification with SuperScript III 
One-Step RT-PCR System (ThermoFisher, Waltham, MA, 
USA). We synthesized complementary DNA by using uni-
12 primers (5′-AGCAAAAGCAGG-3′), and conducted 
real-time PCR with an A(H7N9) detection kit (Shanghai Zj 
Bio-Tech Co., Ltd, Shanghai, China) to detect avian influ-
enza A(H7N9) virus.
Genome Sequencing and Phylogenetic Analysis
Staff of the Guangdong Provincial Center for Disease Con-
trol and Prevention isolated virus from the endotracheal as-
pirate specimen obtained on day 6 of illness onset. Whole- 
genome sequencing was implemented on the Ion Torrent 
S5 platform (ThermoFisher) with a mean read length of 
≈200 bp. We analyzed data predominantly with CLC Ge-
nomics Workbench 7.5.1 software (https://www.qiagen-
bioinformatics.com/products/clc-genomics-workbench/). 
Low-quality reads were trimmed by using CLC trimmer 
with a quality limit set at 0.05. We assembled filtered reads 
de novo in CLC under default parameters. Contigs with 
coverage >10 bp were extracted and blasted against the 
GISAID (Global Initiative on Sharing All Influenza Data) 
databases (http://platform.gisaid.org). Sequences with the 
highest similarity were selected as references for read map-
ping (parameters: length fraction = 0.8, similarity frac-
tion = 0.8). We obtained influenza A genome sequences by 
extracting consensus sequences from the mapping results 
with a coverage depth of >30× at each nucleotide site of 
the 8 gene segments. The viral sequences generated in this 
study (online Technical Appendix Table 3) were submitted 
to the GISAID database.
We used the MEGA software version 5.05 (http://
www.megasoftware.net) to construct phylogenetic trees, 
and maximum likelihood trees were constructed with Phy-
ML (http://www.atgc-montpellier.fr/phyml/) by using the 
general time reversible plus gamma distribution plus pro-
portion of invariable sites model. We estimated node sup-
port by the SH-like aLRT method and report values >0.8. 
Bootstrap values from 1,000 replicates were calculated to 
assess the reliability of the phylogenetic trees.
Serology
A(H7N9)-specific antibody titers were quantified in seri-
ally acquired serum samples by hemagglutination inhibi-
tion (HI) assay by using horse erythrocytes according to 
the World Health Organization recommended protocol 
(http://www.who.int/influenza/gisrs_laboratory/cnic_sero-
logical_diagnosis_hai_a_h7n9_20131220.pdf). A recom-
binant A/PR/8/34 virus with the HA and neuraminidase 
(NA) genes of A/Zhejiang/DTID-ZJU01/2013 (H7N9) 
was used for serologic tests. All bioassays were conducted 
in a Biosafety Level 3 laboratory. Seropositivity was de-
fined as an HI titer >1:40.
Ethical Approval
Guangdong Center for Disease Control and Prevention is 
legally tasked with data collection on patients in the course 
of a public health investigation during an emerging infec-
tious disease outbreak. Thus, informed consent was waived.
Results
This patient initially tested negative for influenza A/B, but 
on day 6, real-time reverse transcription PCR performed 
using an endotracheal aspirate showed positive results 
for A(H7N9) virus RNA. Viral RNA was detectable in 
the patient’s endotracheal aspirate at high levels (>4 log 
RNA copies/mL) until day 17 (Figure 3), was undetect-
able in serum throughout the course of illness, and was 
transiently detected in the feces on day 11. Antibody to 
A(H7N9) virus was first detected in serum collected on 
day 8 (HI titer 1:80); serum titers increased until day 29 
(1:640) (Figure 3).
We performed phylogenetic analyses on the virus 
(designated A/Guangdong/17SF006/2017 [17SF006/17]) 
isolated from the patient on day 6. The HA segment of 
17SF006/17 was related to A(H7N9) clade W2-C (7) (Fig-
ure 4). An insertion that led to the addition of multiple ba-
sic amino acid residues (PEVPKRKRTAR/GL) was found 
at the HA cleavage site, suggesting that this virus might 
be highly pathogenic in birds (Table) (13). A similar mu-
tation was found for 2 other cases of A(H7N9) infection 
identified in Taiwan (A/Taiwan/1/2017) (14) and Guang-
dong Province (A/Guangdong/17SF003/2016, reported 
as A/Guangdong/Th008/2017) (15). The HA and matrix 
sequences of these 3 viruses clustered together in our phy-
logenetic analysis.
We also sequenced and studied the HA and NA genes 
of 7 A(H7N9) viruses isolated from environmental samples 
(from birds at live poultry markets) collected previously in 
the Guangdong Province. Six of the 7 were mixed with 
A(H9N2) viruses, and thus, the genes for the internal pro-
teins could not be analyzed. All of the A(H7N9) viruses 
isolated from the environmental samples had the same HA 
cleavage site sequence motif as the A(H7N9) human vi-
ruses (except for an amino acid change [G] at position −6 
from the cleavage site) and clustered with them in the phy-
logenetic tree, suggesting the emergence of a single sub-
clade of A(H7N9) virus with an HA progressively acquir-
ing HPAI mutations. Similar to other A(H7N9) viruses, the 
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Figure 4. Phylogenetic analysis of the hemagglutinin gene of highly pathogenic avian influenza A(H7N9) viruses in Guangdong 
Province, China, and reference viruses. Maximum likelihood trees were constructed with PhyML by using the general time 
reversible plus gamma distribution plus proportion of invariable sites model. Node support was estimated by the SH-like aLRT 
method, and values >0.8 are shown. Virus clades A, B, and C—previously defined as W2-A, W2-B, and W2-C (5)—are labeled. A/
Guangdong/17SF006/2017 (from a 56-year-old man), A/Guangdong/17SF003/2016, A/Taiwan/1/2017, and environmental isolates are 
underlined. Scale bar indicates nucleotide substitutions per site.
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amino acid substitution G180V in the HA protein, which is 
known to enhance the binding to mammalian α-2,6–linked 
sialic acid receptors, was found.
The NA genes of 17SF006/17, A/Guangdong/17SF003/ 
2016, and the environmental isolates grouped together, but 
A/Taiwan/1/2017 did not cluster, suggesting that the origin 
of this NA gene was distinct (online Technical Appendix 
Figure, panel A). A mutation associated with oseltamivir 
resistance (one leading to R292K substitution in NA) was 
identified in the NA gene of 17SF006/17 virus. The patient 
had been on oseltamivir for 2 days before the mutation 
was detected. Both A/Guangdong/17SF003/2016 and A/
Taiwan/1/2017 also had the mutation associated with os-
eltamivir resistance, but the viruses from the Guangdong 
environmental samples did not. Similar to other A(H7N9) 
viruses, 17SF006/17 had a mutation leading to the S31N 
amino acid substitution in the matrix protein, which is as-
sociated with amantadine resistance. A mutation in PB2 
that causes substitution E627K, which is a key signature 
of mammalian adaptation, was also found in this virus. The 
other viral gene segments of the 3 human viruses are not 
monophyletic and appear to be derived from reassortment 
with genetically diverse A(H7N9) viruses (online Techni-
cal Appendix Figure, panels A–G).
To investigate the potential for human-to-human 
transmission of HPAI A(H7N9), an epidemiologic inves-
tigation was conducted immediately after virus detection 
in the patient. Seventy close contacts (5 family members 
and 65 healthcare workers) were placed under medical 
observation for 2 weeks. None of them showed signs 
of illness.
Discussion
We report the illness and death of a patient in Guangdong 
Province who was infected with a putative HPAI A(H7N9) 
virus carrying an HA cleavage site with multiple basic 
amino acids. Previous A(H7N9) viruses were low patho-
genicity, containing only a single arginine residue at the 
HA cleavage site. Although the HA cleavage site we de-
scribe in this report was not a typical HPAI motif for H7 
viruses, similar motifs have been reported in H7 viruses in 
Chile and Canada that were shown to be highly pathogenic 
in chickens by intravenous pathogenicity tests (13). More 
studies are needed to determine the pathogenicity of these 
putative HPAI A(H7N9) viruses (e.g., direct isolation from 
sick and dying poultry and intravenous pathogenicity in-
dex testing in chickens). Viruses isolated from live poultry 
markets had a sequence motif similar to that of the human 
isolates (identical except for a glycine at the position −6 
from the cleavage site). An additional patient identified in 
Guangdong Province was infected with an A(H7N9) virus 
(A/Guangdong/Th005/2017) with HA cleavage site KG-
KRIAR/GL (15). This evidence suggests that the polybasic 
HA cleavage site was acquired progressively through mul-
tiple mutations within the avian species in a subclade of the 
A(H7N9) viruses.
The patient had reported that chickens in his backyard 
had started dying in the weeks before his disease onset, 
 
Table. Key molecular signatures of avian influenza A(H7N9) virus from patient in Guangdong Province, China, compared with other 
closely related viruses* 
Strain 
HA 
 
NA 
 
M2 
 
PB2 
 
PA 
321–331† G186V‡ Q226L‡ R292K§ S31N¶ E627K# K526R** K702R†† V100A†† 
A/Guangdong/ 
17SF006/2017 
(H7N9)‡‡ 
PEVPKRKRTAR/
GL 
V Q  K  N  K K K  V 
A/Guangdong/ 
17SF003/2016 
(H7N9) 
PEVPKRKRTAR/
GL 
V Q  K  N  E K R  V 
A/Taiwan/1/2017 
(H7N9) 
PEVPKRKRTAR/
GL 
V Q  K  N  K R K  A 
A/Environment/ 
Guangdong/ 
C16283222/2016 
(H7N9) 
PEVPKGKRTAR/
GL 
V Q  R  N  E R K  A 
A/Fujian/3/2016 
(H7N9) 
PEIPKG—-R/GL V L  R  N  K R K  A 
A/Zhejiang/3/2017 
(H7N9) 
PEIPKG—-R/GL V L  R  N  K K K  V 
A/Netherlands/ 
219/2003 (H7N7) 
PEIPKRRRR/GL G Q  R  S  K R K  A 
*HA, hemagglutinin; NA, neuraminidase; NAI, neuraminidase inhibitor; M2, matrix protein 2; PA, polymerase acidic; PB2, polymerase basic 2. 
†Cleavage site. 
‡Receptor binding site. 
§Associated with NAI drug resistance. 
¶Associated with amantadine resistance. 
#Associated with increased virulence in mice. 
**Associated with enhanced viral replication in mammalian hosts. 
††Species-associated signature position. 
‡‡Virus from patient in this report. 
 
RESEARCH
1338 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 23, No. 8, August 2017
indicating the possibility that these chickens were infected 
with an HPAI and that the patient acquired his infection 
from them. However, we do not have direct evidence of 
A(H7N9) infection in these birds, and alternative explana-
tions for their deaths exist. 
A(H7N9) viruses having HA cleavage sites with mul-
tiple basic amino acids were reported in 2 human cases 
in the Guangdong Province and Taiwan (Table) (14,15). 
The HA sequences of these 2 viruses clustered with that 
of A/Guangdong/17SF006/2017 in our phylogenetic tree. 
These viruses also clustered with viruses from the envi-
ronmental samples from Guangdong, which had a similar 
sequence motif (1 amino acid difference) at the cleavage 
site as the human isolates, suggesting the progressive 
emergence of this HPAI motif in a subclade of A(H7N9) 
viruses in this region. Although the HA gene segments 
of these viruses are monophyletic, the other gene seg-
ments are not and have diverse origins, suggesting that 
these HPAI viruses continue to reassort their gene seg-
ments. Introduction of the polybasic cleavage site into 
A(H5N1) was associated with increased viral titers in the 
respiratory tract, increased virus dissemination to distant 
organs, increased death in mice and ferrets (but not in 
macaques), and increased virus replication in endothelial 
cells (16,17).
A question of public health interest is whether acqui-
sition of the polybasic cleavage site in A(H7N9) HA en-
hances pathogenicity of A(H7N9) viruses in humans. Simi-
lar to most patients with A(H7N9) disease (18), the patient 
in this report had underlying comorbidities (diabetes and 
hypertension), which probably contributed to the increased 
disease severity. The clinical progression of the illness to 
fulminant viral pneumonia and ARDS was relatively rapid, 
in spite of commencing oseltamivir on day 4 of illness. The 
patient required mechanical ventilation and became coma-
tose on day 6 of illness and had a sudden cardiac arrest on 
day 7, necessitating ECMO. Myocarditis and encephalitic 
illness were not evident by either clinical observation or 
imaging investigations, and the most likely cause of the 
coma was respiratory failure. One of the other patients in 
Guangdong who had a similar HPAI A(H7N9) virus infec-
tion had less severe illness, indicating that the HA cleav-
age sequence did not invariably increase pathogenicity in 
humans (15).
By day 6 of patient disease onset, 2 days after com-
mencement of oseltamivir, the virus had acquired a muta-
tion leading to an R292K change in the NA protein known 
to be associated with oseltamivir resistance (19,20). The 
other 2 viruses with the same HA cleavage site mutation 
(A/Guangdong/17SF003/2016 and A/Taiwan/1/2017) also 
had this oseltamivir resistance mutation. It is likely that the 
viruses from all 3 patients acquired this resistance mutation 
after commencement of oseltamivir therapy. Although the 
emergence of R292K has been reported before in a minori-
ty of patients following oseltamivir treatment and treatment 
failure (19), mutations causing this amino acid substitution 
have not been found in poultry as of May 30, 2017 (7), and 
accordingly, the resistance mutation was not observed in 
the related environmental samples collected from live poul-
try markets. The frequency with which R292K has been 
detected in patients with the polybasic HA cleavage site is 
a cause for concern. Whether acquisition of the polybasic 
HA cleavage site in the A(H7N9) virus contributes to the 
enhanced probability of the virus acquiring the NA R292K 
during oseltamivir treatment is unknown. Studies of HPAI 
A(H5N1) viruses in vitro and in vivo have demonstrated 
that viruses with polybasic residues at the HA cleavage site 
or the PB2 E627K amino acid change enhances replication 
efficiency, which might increase the likelihood of resis-
tance emerging under the selective pressure of oseltamivir 
therapy (21–23).
NA R292K confers resistance to both oseltamivir and 
peramivir, the antiviral drugs used in this patient’s therapy 
(20). Viral load in the endotracheal aspirates remained high 
for 10 days following commencement of antiviral therapy, 
probably reflecting lack of efficacy of the antiviral regi-
mens. Viral load only began to decline on day 18 of illness, 
probably because of increasing antibody titers. Thus, the 
uncontrolled viral replication and emergence of antiviral 
resistance in this patient possibly contributed to the adverse 
clinical outcome. In spite of the prolonged infection and 
high virus titer within the respiratory tract, virus RNA was 
not detectable in the serum (Figure 3). Thus, systemic dis-
semination of the virus was unlikely. This patient was not 
treated with corticosteroids until day 41, shortly before his 
demise; thus, corticosteroid therapy did not increase viral 
load or facilitate the emergence of antiviral resistance, a 
phenomenon speculated to have occurred in other patients 
in whom oseltamivir resistance mutations arose (19).
The emergence of antibiotic-resistant Acinetobacter 
and other bacteria might also have contributed to the ad-
verse clinical outcome. Detection of CMV DNA in se-
rum (rather than in leukocytes) is suggestive of clinically 
significant CMV viremia following CMV reactivation in 
a seriously ill patient. CMV viremia is an indication for 
ganciclovir therapy in immunocompromised patients, 
which was the rationale for initiating ganciclovir therapy. 
However, the benefit of using ganciclovir in this context 
remains unknown.
The patient had increasing levels of serum creati-
nine and blood urea nitrogen, indicating moderate renal 
dysfunction, and moderately elevated aspartate amino-
transferase, indicating moderate liver dysfunction. Similar 
features have been previously reported in A(H7N9) pa-
tients and are not necessarily indicative of systemic virus 
dissemination (8).
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No evidence of human-to-human transmissibility was 
apparent; family members and healthcare workers who 
were in contact with the patient did not have evidence 
of clinical disease. The HA cleavage site mutation that 
makes avian influenza viruses highly pathogenic in birds 
does not necessarily affect the transmissibility of the virus 
between humans. However, unlike LPAI viruses, which 
are restricted to the chicken respiratory and intestinal 
tracts, HPAI viruses spread systemically within chickens 
and are likely to be found at high titer in multiple organs, 
including muscle. Thus, the risk for zoonotic transmis-
sion through handling or butchering infected poultry and 
consuming undercooked poultry is likely to increase with 
HPAI viruses.
In summary, we report the clinical disease progres-
sion of a patient infected with a mutant A(H7N9) virus 
that acquired sequence motifs similar to those found in 
HPAI viruses. The clinical features of human disease with 
this isolate did not appear to differ from previous infec-
tions with low pathogenicity A(H7N9) viruses, and the 
clinical and virologic evidence suggested that systemic 
dissemination of the virus did not occur. The emergence 
of R292K in NA, which is associated with NA inhibitor 
resistance, probably contributed to the adverse clinical 
outcome. In China, heightened surveillance of A(H7N9) 
in humans with severe respiratory disease and poultry is 
needed to determine how widespread the polybasic HA 
cleavage sequence has become and to monitor for evi-
dence of oseltamivir resistance.
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